Diabetes Mellitus Clinical Trial
Official title:
Multifactorial Pre-Operative Intervention in Diabetes Mellitus
The purpose of this study is to advance the quality of care among inpatients with diabetes in the VHA. When patients with diabetes are admitted to the hospital, there is a greater chance that they will have a complication that lengthens their stay in the hospital. We are testing whether managing their diabetes before admission makes a difference in occurrence of in-hospital complications.
Patients with diabetes that require hospitalization are at increased risk for morbidity and
mortality, especially when undergoing surgery. There is some evidence that intensive glucose
management during hospitalization may improve outcomes. However, no studies have evaluated
intensive diabetes treatment before hospitalization.
Preliminary data from patients having vascular surgery show that those with diabetes have
longer hospital stays, more frequent wound infections, and are more likely to require a
return to the operating room when compared to patients without diabetes. In particular,
insulin-treated patients have even greater peri-operative complications than non-insulin
treated patients with diabetes. However, these data also suggest that a clinical trial to
test the hypothesis that pre-operative intensive management has significant impact on
peri-operative complications would require a very large number of participants to have
adequate power.
Thus, our objective is to conduct a pilot and feasibility study to determine whether an
intervention that involves intensive pre-operative diabetes management can be successfully
implemented and to assess whether trends for benefit are observed. The results of this trial
will support the conduct of a definitive study that tests the effectiveness of such an
intervention in a larger sample of patients.
This is a randomized, parallel group clinical trial in insulin-treated patients with diabetes
mellitus who have been scheduled for elective vascular surgery. We will randomize 46
participants diabetes mellitus: insulin-treated with HbA1c 7.5% or treated with oral agents
with an elevated HbA1c who are scheduled for vascular surgery and in whom a 6 week
pre-operative delay poses no substantial medical risks, as determined by the staff surgeon.
We will exclude individuals with markedly elevated HbA1c or blood pressure; those with
recently manifest cardiovascular disease, and those unable to attend regularly scheduled
follow-up visits during the pre-operative period.
Participants will be randomized to either continue with usual care or participate in a
multifactorial intervention conducted over a 6-week period. During the intervention period,
participants will meet with a care manager and/or endocrinologist on at least 3 occasions and
have telephone follow-up between these visits. They will receive instruction on lifestyle
modifications; measure glucose and blood pressure at home (including the use of a continuous
glucose monitoring device on 2 occasions), and receive care management to optimize glucose,
blood pressure, and lipid lowering, as appropriate.
The primary outcome measure is the percent of screened participants that are eligible and
choose participation Secondary end points will include: participant adherence with the study
protocol, change from baseline in A1c and fructosamine, occurrence of wound infections in the
30-day peri-operative period, a composite of death from cardiovascular causes, non-fatal
myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention,
nonfatal stroke, or amputation as a result of peripheral ischemia; length of hospital stay;
and rate of return to the operating room.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |